(0.33%) 5 116.90 points
(0.30%) 38 355 points
(0.38%) 15 988 points
(-0.87%) $83.12
(5.77%) $2.03
(0.46%) $2 357.90
(0.47%) $27.67
(3.91%) $958.20
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.66%) $93.40
@ $7.03
発行日: 14 2月 2024 @ 23:30
リターン: -23.61%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 3.84 %
Live Chart Being Loaded With Signals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines...
Stats | |
---|---|
本日の出来高 | 37 000.00 |
平均出来高 | 207 780 |
時価総額 | 143.53M |
EPS | $0 ( 2024-03-27 ) |
次の収益日 | ( $-0.890 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.920 |
ATR14 | $0.0230 (0.43%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Roth David | Sell | 10 451 | Common Stock |
2024-03-31 | Stephens Kristin | Buy | 11 666 | Common Stock |
2024-04-01 | Stephens Kristin | Sell | 4 218 | Common Stock |
2024-03-31 | Stephens Kristin | Sell | 11 666 | Restricted Stock Units |
2024-03-31 | Stephens Kristin | Buy | 2 000 | Common Stock |
INSIDER POWER |
---|
54.80 |
Last 100 transactions |
Buy: 2 824 203 | Sell: 497 307 |
ボリューム 相関
Syros Pharmaceuticals Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Syros Pharmaceuticals Inc 相関 - 通貨/商品
Syros Pharmaceuticals Inc 財務諸表
Annual | 2023 |
収益: | $9.94M |
総利益: | $7.68M (77.33 %) |
EPS: | $-5.81 |
FY | 2023 |
収益: | $9.94M |
総利益: | $7.68M (77.33 %) |
EPS: | $-5.81 |
FY | 2022 |
収益: | $14.88M |
総利益: | $11.91M (80.06 %) |
EPS: | $-3.90 |
FY | 2021 |
収益: | $23.49M |
総利益: | $23.49M (100.00 %) |
EPS: | $-18.80 |
Financial Reports:
No articles found.
Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。